Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 294

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 294
---
 of Neurodegenerative
Diseases”. The patent, which is set to expire on April 9, 2037, claims a method developed by DiamiR for detecting a neurodegenerative
disorder (ND) in a subject, wherein the ND is frontotemporal dementia (FTD) or amyotrophic lateral sclerosis (ALS) (and further differentiating
between FTD or ALS and other neurodegenerative disorders) as well as a method for monitoring changes in development of FTD or ALS in a
subject and a method for monitoring the effect of a therapeutic agent on development of FTD or ALS. In addition, a foreign counterpart
has issued in the European Patent Organization; the validation is pending in France, Germany, Italy, Ireland, Spain, Switzerland and the
UK.

On April 13, 2021, the USPTO issued to DiamiR
U.S. Patent No. 10,975,436, entitled “Methods of Using miRNA from Bodily Fluids for Diagnosis and Monitoring of Neurodevelopmental
Disorders”. The patent, which is set to expire on February 26, 2037, claims methods developed by DiamiR for detecting Rett Syndrome
(RTT), monitoring changes in development of RTT, and treating RTT in a subject, or selecting subjects for enrollment in a clinical trial
involving treatment of RTT, as well as methods for monitoring the effect of a treatment on development of RTT and methods for identifying
a compound useful for slowing down the progressing or for treating RTT in a subject.

On June 27, 2024, DiamiR’s
European Patent Application No. 17 771018.3 titled: “Methods of using miRNAs from bodily fluids for detection and differentiation
of neurodegenerative diseases” was granted by the European Patent Office and the mention of grant was published in the European
bulletin on July 24, 2024 and the European patent will be granted under number 3 433 381. The patent, which is set to expire in March
2037, claims the use of methods developed by DiamiR for early diagnosis of amyotrophic lateral sclerosis (ALS).

DiamiR’s team has developed a substantial
know-how in extracting, detecting, and analyzing miRNAs. All statistical analyses are performed with the proprietary software developed
by DiamiR, which is currently maintained as trade secret. Data analysis performed with DiamiR